Total raised
$295.0M
Last: Series B 2021-10
Stage
Series B
Founded
2019
Headcount
192
HQ
Tel Aviv-Yafo
Sector
Health Tech & Life Sciences
About
Immunai is developing a proprietary data set of multi-omic, immune-centric peripheral tissue analyses. The company's advanced analytics and data-visualization interface allows researchers to comprehensively view and interrogate data and to derive novel conclusions on the underlying mechanisms of disease.
The platform is currently being used to develop and refine cell therapies for neuroblastoma in conjunction with the Baylor College of Medicine.
Funding history · 3 rounds · $295.0M total
2021-10
Series B
$215.0M
2021-02
Series A
$60.0M
2020-05
Seed
$20.0M
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Business SoftwareIT, R&D & Data SolutionsData Analysis & Decision SupportHealth Tech & Life SciencesDigital HealthcareMedical Decision SupportPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Artificial IntelligenceDeep LearningMachine Learning
Target customers
Healthcare & Life SciencesHealthcareLaboratoriesProvidersLife SciencesPharmaceuticals
Business model
B2B
Tags
clinical-trialsimmunotherapyunicorn-2021digital-healthcarehospitalsimmunologydata-analyticsactionable-insightspharma-companiescancerautoimmune-diseasesartificial-intelligencemachine-learningdeep-learningcells